14 Addressing Pain in Patients with Solid Tumours and Bone Metastases Receiving the Bone-targeted Therapies Denosumab or Zoledronic Acid

G. Mayer, G. Fitzpatrick, G. Frey, H. Wigginton, S. Woodhead, C.S. Cleeland, Y. Qian, A. Braun, K. Chung. Kantonsspital Graubunden, Medicine, Chur, Switzerland; Urology Associates/Urologic Medical Research, Urology, Kitchener, Canada; The University of Arizona Cancer Center, Oncology, Tucson, USA; Cancer Research UK Clinical Centre, Non Surgical Oncology, Leeds, United Kingdom; Sydney Adventist Hospital, Oncology, Wahroonga, Australia; MD Anderson Cancer Center, Internal Medicine, Houston, USA; Amgen Inc., Biostatistics and Global Safety, Thousand Oaks, USA; Amgen Inc., Hematology/Oncology, Thousand Oaks, USA; Amgen Inc., Global Health Economics, Thousand Oaks, USA